Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ® ...

Valneva (VALN) stock rose after the company posted new Phase 3 trial data for its chikungunya vaccine, Ixchiq, in adolescents aged 12-17. Read more here.

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Although not listed as a hemorrhagic fever virus, illness caused by CHIKV can ... A definitive diagnosis of Chikungunya infection can be made only with the aid of laboratory support since ...

Maharashtra witnessed a significant rise in chikungunya cases this year, with 5,757 infections. Patients are experiencing prolonged after-effects like joint pain, fatigue, and neurological ...

The existing RT-PCR test systems are time consuming and labor-intensive, with a very high risk of contamination primarily due to post-PCR handling leading to carry over. In addition, the majority ...

Now, researchers used cryoelectron microscopy (cryo-EM) to elucidate the structure of the Nipah virus polymerase complex (the ...

Researchers have profiled the molecular structure and features of a key part of the deadly Nipah virus. Experiments in cells showe how changes in the viral polymerase -- a protein involved in viral ...

The work provides a detailed three-dimensional picture of the virus's polymerase and its key features. Understanding the ...